Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410824 | 1.00 | PARP1 (0.39) | PARP1HDAC9KDM4EMAPTDPP9 | |
| SCHEMBL29511535 | 1.00 | PARP1 (0.39) | PARP1HDAC9KDM4EMAPTDPP9 | |
| SCHEMBL199421 | 1.00 | PARP1 (0.39) | PARP1HDAC9KDM4EMAPTDPP9 | |
| SCHEMBL199422 | 1.00 | PARP1 (0.39) | PARP1HDAC9KDM4EMAPTDPP9 | |
| SCHEMBL14325919 | 0.89 | AKR1C1 (0.42) | HDAC9DPP9DPP7MEN1KMT2A | |
| SCHEMBL29476532 | 0.86 | HDAC9 (0.44) | HDAC9DPP9DPP7CXCR5 | |
| SCHEMBL122942 | 0.86 | HDAC9 (0.44) | HDAC9DPP9DPP7CXCR5 | |
| SCHEMBL7532846 | 0.85 | PARP1 (0.42) | PARP1HDAC9DPP9DPP7ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1168670 | 0.84 | HDAC9 (0.43) | HDAC9DPP9DPP7CXCR5 | |
| Hydrochloric Acid SCHEMBL9174977 | 0.84 | PARP1 (0.41) | PARP1HDAC9DPP9DPP7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4665374-A1 | METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES | Endevica Bio, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2025123059-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2024177907-A2 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| WO-2024173905-A1 | METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES | ENDEVICA BIO, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| WO-2004094412-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2004-11-04 | — | — | WO | claimed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | claimed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| US-6743373-B1 | REAGENT BASED ON ENANTIOPURE AMINO ACID IN WHICH AMINO GROUP CARRIES ACTIVATING GROUP TO FORM ACTIVE PRECURSOR OF ISOCYANATE GROUP AND CARBOXYL GROUP IS SUBSTITUTED; SEPARATION OF ENANTIOMERS HAVING FREE FUNCTIONAL GROUP | SOLVAY (SOCIETE ANONYME) (BE) | 2004-06-01 | — | — | US | claimed |
| EP-1046627-B1 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (BE) | 2004-02-11 | — | — | EP | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| US-6338945-B1 | CONCURRENT SCREENING OF OLIGOPEPTIDE LIBRARIES SYNTHESIZED ON SOLID PHASE SUPPORTS TO ISOLATE BIOACTIVE MOLECULES WHICH ELICIT CYTOLYTIC ACTIVITY | GENZYME CORPORATION | 2002-01-15 | — | — | US | claimed |
| US-5780589-A | DIPEPTIDES, TRIPEPTIDES OR CYCLIC PEPTIDES AS ANTAGONIST OF OPIOID RECEPTORS TREATING DRUG ABUSE, DRUG DEPENDENCE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-07-14 | — | — | US | claimed |
| WO-1996016982-A2 | ULTRASELECTIVE OPIOIDMIMETIC PEPTIDES AND PHARMACOLOGICAL AND THERAPEUTIC USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | PARP1 4866/4885HDAC9 2074/4885KDM4E 1030/4885 |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | DNPEP, DAO, ANPEP | PARP1 4135/4885HDAC9 4873/4885KDM4E 4407/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | PARP1 2013/4885HDAC9 1261/4885KDM4E 1839/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | PARP1 3012/4885HDAC9 1444/4885KDM4E 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.